Suppr超能文献

日本阿尔茨海默病诊断与管理的流行病学、相关负担及当前临床实践

Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer's disease in Japan.

作者信息

Montgomery William, Ueda Kaname, Jorgensen Margaret, Stathis Shari, Cheng Yuanyuan, Nakamura Tomomi

机构信息

Global Patient Outcomes & Real World Evidence, Eli Lilly Australia, Sydney, NSW, Australia.

Medical Development Unit-Japan, Eli Lilly Japan KK, Kobe, Japan.

出版信息

Clinicoecon Outcomes Res. 2017 Dec 28;10:13-28. doi: 10.2147/CEOR.S146788. eCollection 2018.

Abstract

The burden of dementia in Japan is large and growing. With the world's fastest aging population, it is estimated that one in five elderly people will be living with dementia in Japan by 2025. The most common form of dementia is Alzheimer's disease (AD), accounting for around two-thirds of dementia cases. A systematic review was conducted to examine the epidemiology and associated burden of AD in Japan and to identify how AD is diagnosed and managed in Japan. English and Japanese language databases were searched for articles published between January 2000 and November 2015. Relevant Japanese sources, clinical practice guideline registers, and reference lists were also searched. Systematic reviews and cohort and case-control studies were eligible for inclusion, with a total of 60 studies included. The most recent national survey conducted in six regions of Japan reported the mean prevalence of dementia in people aged ≥65 years to be 15.75% (95% CI: 12.4, 22.2%), which is much higher than the previous estimated rate of 10% in 2010. AD was confirmed as the predominant type of dementia, accounting for 65.8% of all cases. Advancing age and low education were the most consistently reported risk factors for AD dementia. Japanese guidelines for the management of dementia were released in 2010 providing specific guidance for AD about clinical signs, image findings, biochemical markers, and treatment approaches. Pharmacotherapies and non-pharmacotherapies to relieve cognitive symptoms were introduced, as were recommendations to achieve better patient care. No studies reporting treatment patterns were identified. Due to population aging and growing awareness of AD in Japan, health care expenditure and associated burden are expected to soar. This review highlights the importance of early detection, diagnosis, and treatment of AD as strategies to minimize the impact of AD on society in Japan.

摘要

日本痴呆症的负担巨大且呈增长趋势。由于日本是全球老龄化速度最快的国家,据估计,到2025年,日本每五名老年人中就有一人患有痴呆症。最常见的痴呆症类型是阿尔茨海默病(AD),约占痴呆症病例的三分之二。本研究进行了一项系统综述,以考察日本AD的流行病学情况及相关负担,并确定日本对AD的诊断和管理方式。检索了英文和日文数据库中2000年1月至2015年11月发表的文章。还检索了相关日文资料、临床实践指南登记册及参考文献列表。符合纳入标准的有系统综述、队列研究和病例对照研究,共纳入60项研究。在日本六个地区进行的最新全国性调查显示,≥65岁人群中痴呆症的平均患病率为15.75%(95%CI:12.4,22.2%),远高于2010年之前估计的10%。AD被确认为痴呆症的主要类型,占所有病例的65.8%。年龄增长和低教育水平是AD痴呆症最一致的报告风险因素。2010年发布了日本痴呆症管理指南,为AD的临床体征、影像学表现、生化标志物及治疗方法提供了具体指导。介绍了缓解认知症状的药物治疗和非药物治疗方法,以及改善患者护理的建议。未发现报告治疗模式的研究。由于日本人口老龄化以及对AD的认识不断提高,预计医疗保健支出及相关负担将飙升。本综述强调了AD早期检测、诊断和治疗的重要性,将其作为在日本尽量减少AD对社会影响的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/162d/5749549/81d6e84aafe1/ceor-10-013Fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验